IL10 and neoplasm: A recombinant thymidine kinase (TK)-deleted Lister strain vaccinia OV armed with murine IL-10 was able to elicit tumour rejection in two murine pancreatic ductal adenocarcinoma (PDAC) models by prolonging the oncolytic potential of the OV and modulating innate and adaptive immune responses [100].